MicroRNAs Based Therapy of Hypertrophic Cardiomyopathy: The Road Traveled So Far

Catarina Roma-Rodrigues, Luis R. Raposo, Maria Alexandra Núncio de Carvalho Ramos Fernandes

Research output: Contribution to journalLiterature review

7 Citations (Scopus)

Abstract

Hypertrophic cardiomyopathy (HCM) is an autosomal dominant disease characterized by variable expressivity, age penetrance, and a high heterogeneity. The transcriptional profile (miRNAs, mRNAs), epigenetic modifications, and posttranslational modifications seem to be highly relevant for the onset of the disease. miRNAs, small noncoding RNAs with 22 nucleotides, have been implicated in the regulation of cardiomyocyte function, being differentially expressed in several heart diseases, including HCM. Moreover, a different miRNA expression profile in the various stages of HCM development is also observed. This review summarizes the current knowledge of the profile of miRNAs characteristic of asymptomatic to overt HCM patients, discussing alongside their potential use for diagnosis and therapy. Indeed, the stability and specificity of miRNAs make them suitable targets for use as biomarkers for diagnosis and prognosis and as therapeutical targets.

Original languageEnglish
Article number983290
JournalBioMed Research International
DOIs
Publication statusPublished - 2015

Keywords

  • CARDIAC-HYPERTROPHY
  • CIRCULATING MICRORNAS
  • RNA-INTERFERENCE
  • GOLD-NANOBEACONS
  • HEART-FAILURE
  • DISEASE
  • THERAPEUTICS
  • GENES
  • RECOGNITION
  • TRANSLATION

Cite this